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Summary
We have determined the 3.2 A˚ X-ray crystal structure of the extracellular domain of the human epidermal growth factor
receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal
antibody also known as 2C4 or Omnitarg. Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a
binding pocket necessary for receptor dimerization and signaling. The ErbB2-pertuzumab structure, combined with earlier
mutagenesis data, defines the pertuzumab residues essential for ErbB2 interaction. To analyze the ErbB2 side of the
interface, we have mutated a number of residues contacting pertuzumab and examined the effects of these mutations on
pertuzumab binding and ErbB2-ErbB3 heterodimerization. We have also shown that conserved residues previously shown
to be necessary for EGF receptor homodimerization may be dispensible for ErbB2-ErbB3 heterodimerization.
Introduction membrane helix, a tyrosine kinase domain most closely related
to the Janus kinases and in the same family as other receptor
Epidermal growth factor receptors (also known as ErbBs) and tyrosine kinases (Hanks and Hunter, 1995), and a C-terminal
their ligands exist in all higher eukaryotes, including C. elegans tail (the length of which varies between family members) con-
(Aroian et al., 1990) and Drosophila (Livneh et al., 1985; Wads- taining a number of tyrosine phosphorylation sites that serve
worth et al., 1985), and have been implicated in a number of as a scaffold for adaptor molecules and enzymes to facilitate
cancers due to dysregulation or mutation of the ErbB genes downstream signaling (Jorissen et al., 2003; Schlessinger,
(Burgess et al., 2003; Holbro et al., 2003; Yarden and Sliwkow- 2000).
ski, 2001). The mammalian ErbB system contains four receptors, At least twelve ligands are known to bind mammalian ErbBs,
40%–45% identical to one another, which arose from a series including epidermal growth factor (EGF) and neuregulins (or
of gene duplications early in vertebrate evolution (Stein and heregulins) (Falls, 2003). A comparison of structures of ErbB3
Staros, 2000). The ErbBs have a common architecture, details and EGF receptor monomers versus a ligand-bound EGFR di-
of which have been revealed recently by a series of structures mer shows that the ligand binds at a site between domains I and
of the extracellular domains of EGF receptor (EGFR or ErbB1) III and induces (or at least stabilizes) a dramatic conformational
(Ferguson et al., 2003; Garrett et al., 2002; Ogiso et al., 2002), change in the receptor extracellular domain (Cho and Leahy,
ErbB2 (HER2) (Cho et al., 2003; Garrett et al., 2003), and ErbB3 2002; Ferguson et al., 2003; Garrett et al., 2002; Ogiso et al.,
(HER3) (Cho and Leahy, 2002), as well as the intracellular kinase 2002). ErbB2 is the only ErbB for which no ligand has been
found; the structure of the ErbB2 extracellular domain showsdomain of EGFR (Stamos et al., 2002). The ErbBs are type
1 transmembrane proteins, with a ligand binding extracellular that the ligand binding site has closed up so that domains I and
III contact each other directly (Cho et al., 2003; Garrett et al.,portion containing four domains (I, II, III, and IV), a single trans-
S I G N I F I C A N C E
ErbB2 is overexpressed in a number of types of cancer, particularly breast cancer, where overexpression correlates strongly with a
more aggressive disease and poorer survival rates. The anti-ErbB2 monoclonal antibody trastuzumab (Herceptin) is indicated for
patients whose metastatic tumors overexpress ErbB2. In contrast, pertuzumab (Omnitarg) is currently being evaluated in Phase II
clinical trials in patients whose breast, non-small cell lung, prostate, or ovarian tumors do not contain the amplified ErbB2 gene. Our
ErbB2-pertuzumab structure clearly shows how pertuzumab inhibits ErbB2s function as a coreceptor in ligand-mediated ErbB signaling,
and provides a framework for interpretation of previous pertuzumab mutagenesis data.
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Figure 1. The ErbB2-pertuzumab complex
A: A ribbon representation of chains B, E, and F
from the ErbB2-pertuzumab complex is shown in
stereo. ErbB2 is colored by domain, with domain
I (residues 1–195) in green, domain II (196–320)
in blue, domain III (321–488) in purple, and do-
main IV (489–560) in gray. Pertuzumab is colored
by domain and chain, with the light chain vari-
able domain (residues 1–109) in light yellow,
heavy chain variable domain (1–113) in gold,
light chain constant domain (110–214) in pink,
and heavy chain constant domain (114–216) in
red. Glycosylation on ErbB2 is shown in stick form,
with carbons colored green, nitrogens blue, and
oxygens red.
B: A composite-omit electron density map of a
portion of the ErbB2-pertuzumab interface, con-
toured at 1.3 sigma, is shown as a blue mesh.
The refined ErbB2-pertuzumab model is superim-
posed, with side chains in stick form and back-
bone in ribbon form. Carbons are colored by
domain as in A: ErbB2 domain II in blue, and
pertuzumab VH in gold.
2003). The residues comprising the former binding site are not the molecule, and makes most of the contacts seen in the EGF
receptor dimer (Garrett et al., 2002; Ogiso et al., 2002). It shouldconserved relative to the rest of the ErbB family (Garrett et al.,
2003), suggesting that ErbB2 is no longer capable of binding a be noted that the open conformation of EGFR has not yet been
observed except in the context of an EGFR homodimer. Theligand.
Ligand-induced dimerization provides the normal down- ErbB2 extracellular domain is always in the open conformation,
even when monomeric (Cho et al., 2003; Garrett et al., 2003),stream signaling mechanism for the ErbBs (Burgess et al., 2003).
A possible structural mechanism for dimerization is suggested which may explain why it is the preferred dimerization partner
for the other three family members (Graus-Porta et al., 1997).by the ligand-induced conformational change. When unli-
ganded, the extracellular domain of EGFR and ErbB3 (and pre- By mechanisms that are still unclear structurally, dimerization
brings the intracellular kinase domains of the two ErbBs intosumably ErbB4) is in a “closed” conformation, with a  hairpin
in domain II interacting with a portion of domain IV (Cho and proximity, allowing transphosphorylation of tyrosines on the
C-terminal tail of one ErbB by the kinase domain of the otherLeahy, 2002; Ferguson et al., 2003). In the ligand-bound, “open”
state, the domain II hairpin now protrudes out from the rest of (Jorissen et al., 2003), and the consequent recruitment of various
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enzymes and adaptor molecules for further downstream signal- Table 1. Data collection and refinement statistics
ing (Olayioye et al., 2000). Data collection statistics ErbB2-pertuzumab complex
ErbB2 overexpression in breast cancer correlates well with
Space group P43 21 2increased tumor growth rates, higher metastatic potential, and
Unit cell (A˚) 139.4, 139.4, 356.9
poorer long-term survival rates for the patient (Holbro et al., Beamline, wavelength ALS 5.0.2, 1.00 A˚
2003; Paik and Liu, 2000; Ross and Fletcher, 1998; Slamon Unique reflections 56351
Resolution (A˚) 30.0–3.25 3.37–3.25et al., 1987). A number of therapeutic approaches are being
Rsym 0.116 0.691developed to block the effects of ErbB2 overexpression (Ar-
Completeness (%) 99.9 100.0teaga, 2003; Fry, 2003), including the humanized monoclonal Avg. redundancy 8.2 8.3
antibodies trastuzumab (Carter et al., 2000) and pertuzumab I/(I) 19.3 3.3
(2C4 or Omnitarg). Trastuzumab is approved for metastatic
Refinement statistics
breast cancer patients whose tumors overexpress ErbB2 (Cob-
Resolution (A˚) 15.0–3.25leigh et al., 1999; Slamon et al., 2001; Vogel et al., 2002), while
Reflections used (free) 52816 (3024)pertuzumab is currently in phase II clinical trials. Trastuzumab R factor 0.224
and pertuzumab bind to different epitopes in the the extracellular Rfree 0.268
RMS deviationsdomain of ErbB2, as has been seen functionally (Fendly et al.,
bonds (A˚) 0.0091990) and structurally (Cho et al., 2003, and this work). Pertuzu-
angles () 1.27mab binding mediates the same antibody-dependent cytotoxic
Ramachandran statistics
effects as trastuzumab binding (Clynes et al., 2000) (K. Totpal, most favored (%) 81.4
personal communication), although it does not block ErbB2 additional allowed (%) 17.4
outliers (%) 0.3shedding as trastuzumab does (Molina et al., 2001). In addition
Model contentsto cytotoxic effects, pertuzumab binding directly inhibits ErbB2
ErbB2 residues 1123association with its partner receptors, blocking the signaling pertuzumab residues 872
cascade at its source (Agus et al., 2002). In experimental sys- sugars 12 NAG, 1 man
tems where ErbB2 is activated but not overexpressed, the Fab
Rsym  
hkl
|I I|/
hkl
I R factor  
hkl
|F(obs)|  |F(calc)|/
hkl
|F(obs)|fragment of pertuzumab, which will not cause antibody-depen-
NAG  -D-N-acetylglucosamine; man  -D-mannosedent cytotoxicity, appears to be just as effective as the intact
MAb at inhibiting ErbB2-mediated signaling, in contrast to the
ineffectiveness of the trastuzumab Fab (Agus et al., 2002; Kelley
et al., 1992). This property may explain why pertuzumab, unlike
trastuzumab, is effective against a broad range of cancers which related by a noncrystallographic 2-fold axis next to residue 162
do not express ErbB2 at high levels (Agus et al., 2000, 2002; in domain I; this domain I-domain I interaction buries only 500 A˚2
Mann et al., 2001; Mendoza et al., 2002). per monomer and is probably not biologically relevant. One
To more fully understand the mechanism of action of pertu- complex (chains B, E, and F) is slightly better ordered than the
zumab, we have determined the cocrystal structure of the pertu- other, and is shown in Figure 1A. After finding both copies of
zumab Fab bound to the extracellular domain of ErbB2. This ErbB2 by molecular replacement, it was possible to locate the
structure represents the pharmacologically relevant complex, variable domains of the two pertuzumab Fabs in a subsequent
given the efficacy of the pertuzumab Fab in vitro and in vivo molecular replacement search, then finally place the constant
(Agus et al., 2002). Previous structural and mutagenic analysis domain of the Fabs. The structure has been refined to an R
of pertuzumab (Vajdos et al., 2002) can now be reinterpreted factor of 22.4% (free R 26.8%), with acceptable model geometry
to provide an understanding of pertuzumab binding from one (Table 1). While peripheral portions of the structure are not well
side of the interface. To analyze the other side of the interface, ordered (see below), the interface between ErbB2 and pertuzu-
we have mutated a number of ErbB2 residues in and around mab has clear electron density (Figure 1B).
the pertuzumab binding site, and examined the effects of these The structure of ErbB2 in the ErbB2-pertuzumab complex
mutations on pertuzumab binding, as well as ErbB2-ErbB3 het- is very similar to its structure alone and in complex with trastuzu-
erodimerization. Finally, the overlap between the pertuzumab mab (Cho et al., 2003). The extracellular domain of ErbB2 is
binding site on ErbB2 and the probable heterodimer interface divided into four domains, designated I, II, III, and IV (Figure
suggests that the binding of the antibody sterically interferes 1A). I and III are structurally very similar: a repeating sequence
with ErbB2 dimerization and signaling. of hydrophobic residues, largely leucines, causes these do-
mains to fold into a “ helix” with sides formed by three parallel
Results  sheets. This architecture is distantly related to the classical
leucine-rich repeats (Ward and Garrett, 2001). Residues 102–
110 form an insertion in the leucine repeat motif of domain I,ErbB2-pertuzumab structure
The soluble extracellular domain of ErbB2 (Hudziak and Ullrich, and are disordered in this structure. Domains II and IV are also
similar to each other in structure, being composed of disulfide-1991) was crystallized in complex with the Fab fragment of the
anti-ErbB2 monoclonal antibody pertuzumab (2C4) (Vajdos et bonded modules, small structural units held together by one or
two disulfide bonds (Burgess et al., 2003). Domain II containsal., 2002). The structure of this complex was solved to 3.25 A˚
by molecular replacement with the program AMoRe (Navaza, seven disulfide-bonded modules, with an eighth module being
structurally part of domain I. Unlike domain IV, domain II con-1994), using the structure of rat ErbB2 extracellular domain
(Cho et al., 2003) as a search model. There are two ErbB2- tains an insertion (residues 247–266) in its central disulfide-
bonded module which forms a  hairpin that protrudes frompertuzumab complexes in the asymmetric unit of this crystal,
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Figure 2. The ErbB2-pertuzumab binding site
A: Overview of the binding site. The four pertuzu-
mab Fab CDRs which interact with ErbB2 are
shown in ribbon representation, as is the “70s
loop” (heavy chain residues 67–82). ErbB2 is
shown in surface form, colored by domain as in
Figure 1A.
B: Interactions of CDRs H1 and H2 with ErbB2.
Selected residues from ErbB2 and pertuzumab
are shown in stick form, with the surrounding
backbone in ribbon form. Hydrogen bonds are
indicated as black lines. CDRs are labeled near
the base of their  hairpins.
C: Interactions of CDRs H3 and L2 with ErbB2.
A representation similar to B, with heavy chain
carbons and ribbons in gold, and light chain in
yellow.
the rest of the protein. This  hairpin protrusion is also seen in rotated by 20 relative to the rest of the protein. This domain
has little contact with domain III, and is positioned in this crystaleach monomer of the EGFR homodimer, where it forms one
side of the dimerization interface (Garrett et al., 2002; Ogiso et primarily by contacts with symmetry-related Fab molecules.
Electron density for domain IV steadily deteriorates with increas-al., 2002). When compared to the structure of ErbB2 alone (Cho
et al., 2003), domain IV in the ErbB2-pertuzumab complex is ing distance from domain III, eventually becoming untraceable
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after residue 550 (in chain A; 560 in chain B). The ErbB2 in this
complex is more heavily glycosylated (20 kDa of sugar by
SDS-PAGE) than the material used in previous crystal structures
(Cho et al., 2003), and each of the four N-linked glycosylation
sites in the ordered portion of the protein has 1–3 well-ordered
sugars attached to it (Figure 1A).
Outside of the complementarity-determining regions (CDRs),
pertuzumab is identical in sequence to trastuzumab (Carter et
al., 1992); consequently, the local structure of the pertuzumab
Fab in the ErbB2-pertuzumab complex is largely the same as
that of the trastuzumab Fab, the chief difference being that
the elbow angle (the angle between the variable and constant
domains of the Fab) is 175, 20 larger than in the structure
of the trastuzumab Fab (Eigenbrot et al., 1993), and30 larger
than in the structure of the pertuzumab Fab alone (Vajdos et
al., 2002). The conformation of CDR H3 has been substantially
altered by binding to ErbB2, compared to the largely similar
conformations of this loop in free pertuzumab and in trastuzu-
mab (Eigenbrot et al., 1993; Vajdos et al., 2002). The constant
domains of the two pertuzumab Fabs do not obey the same
noncrystallographic symmetry as the rest of the complex, being
positioned primarily by nonequivalent crystal contacts. The con-
stant domain of one of the two Fabs (chains C and D) is poorly
ordered, although the variable domain for this Fab is well or-
dered.
Figure 3. Effect of alanine substitutions on pertuzumab binding to ErbB2
ErbB2-pertuzumab binding interface
A: Binding of pertuzumab Fab to various ErbB2 mutants was measured by
The pertuzumab Fab is bound to ErbB2 near the junction of ELISA as described in the Experimental Procedures; curves are shown for
domains I, II, and III (Figure 1A). This contact buries 1210 A˚2 on wild-type (WT) ErbB2 and for selected mutants with little or no effect (T290A
or P315A), a moderate effect (S288A or H296A), or a severe effect (S288A/the ErbB2 side of the interface, with 1147 A˚2 in domain II and
H296A or L295P/H296N) on pertuzumab binding. Error bars represent theonly 63 A˚2 in domain I. Contact is primarily made with the heavy
standard error from three experiments.
chain of the Fab (878 A˚2 versus 236 A˚2 for the light chain). As B: EC50 values determined by ELISA for various ErbB2 single and double
expected, most of the ErbB2-pertuzumab contacts involve the mutants are shown normalized by the EC50 for wild-type ErbB2 (3 nM). The
S288A/H296A, L295A/H296A, and L295P/H296N double mutants had no de-CDRs of the Fab, although the dimerization hairpin of domain
tectable binding to pertuzumab, as indicated by asterisks.II lies along the side of the heavy chain variable domain (Figure
2A). Despite the contact with the Fab, the conformation of the
dimerization hairpin is essentially the same as that seen in the
free and trastuzumab-bound ErbB2 structures as well as that
ErbB2 mutagenesis and pertuzumab inhibitionin the EGF receptor dimer: 0.7, 1.0, and 1.3 A˚ C rmsd, respec-
To assess the relative importance of the pertuzumab Fab-ErbB2tively, for 59 residues surrounding the  hairpin (Cho et al.,
binding interactions described above, and to complement previ-2003; Ogiso et al., 2002).
ous pertuzumab mutagenesis studies (Vajdos et al., 2002), bind-The interface between ErbB2 and pertuzumab is primarily
ing affinities were determined for a number of select ErbB2polar, with few hydrophobic or charged residues in the interface.
mutants. Alanine or other substitutions were made in the contextThe largest hydrophobic patch lies outside the main CDR sur-
of full-length ErbB2 that was epitope tagged with gD (Paborskyface, between Ile 58 and Tyr 59 (heavy chain), Tyr 94 (light
et al., 1990; Schaefer et al., 1999) to allow for verification ofchain), and Tyr 252 and Phe 257 (ErbB2). (For consistency with
expression and to facilitate binding analysis. Recombinantprevious work on the pertuzumab Fab [Vajdos et al., 2002], we
ErbB2 proteins were expressed transiently in COS-7 cells, whichhave chosen to use a modified Kabat numbering rather than
were then lysed with nonionic detergent. ErbB2 was then cap-sequential numbering for pertuzumab residues.) Residues
tured from these lysates on anti-gD coated plates. Pertuzumab30–32 on CDR H1 and 52–53 on CDR H2 make an extensive
Fab binding affinities to the captured ErbB2 were measurednetwork of hydrogen bonds with main chain and side chain
by ELISA. The EC50 for each mutant was determined using aatoms (Figure 2B). His 245 of ErbB2 is tightly sandwiched be-
4-parameter fit of the binding curves (Figure 3A), and these datatween Ile 244 and Gly 55 of CDR H2. Although not technically
were used to calculate the EC50 ratio for the mutant versus thea CDR, the loop containing residues 72–76 makes contacts with
wild-type (the mut/wt ratio) to give a measure of the severity ofErbB2, including the only contact with domain I, a hydrogen
each mutation (Figure 3B). Ratios greater than 1 indicate abond between Lys 75 of pertuzumab and Gln 156 of ErbB2.
deleterious mutation. Alanine substitution in any one of residuesFinally, CDR H3 makes hydrophobic and hydrogen bond con-
His 245, Val 286, Ser 288, Leu 295, His 296, or Lys 311 signifi-tacts with residues Lys 311 and His 296 of ErbB2. His 296 is
cantly reduces pertuzumab Fab binding affinity for ErbB2, whilethoroughly buried upon pertuzumab binding, being surrounded
substitution in residues Phe 257, Thr 268, Thr 290, and Pro 315by Tyr 49 and Tyr 55 of the light chain, and Leu 96 and Tyr 99B
(modified Kabat numbering) of the heavy chain (Figure 2C). results in mut/wt ratios not significantly above 1. Double alanine
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Figure 4. Effect of ErbB2 alanine substitutions on ErbB2-ErbB3 heterodimerization
A: COS-7 cells were cotransfected with ErbB2 wild-type (left panel) or the ErbB2(S288A/H296A) double alanine mutant (right panel) along with ErbB3.
Transfected cells were pretreated with or without 100 nM pertuzumab for 1 hr, and stimulated with 2 nM HRG or binding buffer as indicated for 10 min at
room temperature. Lysates were prepared and ErbB2-ErbB3 heterodimers were immunoprecipitated with agarose-coupled polyclonal anti-ErbB3 antibody,
and ErbB2 receptor activation was evaluated by Western blotting with phosphospecific anti-ErbB2 antibody (-PErbB2), or anti-gD antibody (-gD) to
detect ErbB2-ErbB3 complexes. Lysates were evaluated for expression of ErbB2 and ErbB3 construct expression with anti-gD or anti-ErbB3 (-ErbB3) antibodies,
respectively.
B: A sequence alignment of human ErbB2 and neu is shown for a portion of domain II. The bars above each residue indicate the fraction of the side chain
solvent-accessible surface area, which is buried upon pertuzumab binding.
C: COS-7 cells were cotransfected with alanine mutant ErbB2 and wild-type ErbB3 expression plasmids, stimulated with 2 nM HRG for 10 min at room
temperature, and assayed for HRG-dependent ErbB2 phosphorylation and heterodimerization in a coimmunoprecipitation assay similar to that pre-
sented in A.
substitutions in contact residues 245/296, 286/296, or 311/296 dependent receptor phosphorylation. While pertuzumab can
block HRG-dependent activation in wild-type ErbB2 transfectedreduce binding further, and the 288/296 double mutation lacks
any detectable binding to pertuzumab Fab in this assay. In cells, inhibition is not observed in ErbB2(L295P/H296N) trans-
fected cells (Supplemental Figure S1 as http://www.cancercell.addition, the pertuzumab Fab is unable to prevent HRG-depen-
dent heterodimerization of the 288/296 double mutant ErbB2 org/cgi/content/full/5/4/317/DC1).
with ErbB3 (Figure 4A). In agreement with our previous studies
(Agus et al., 2002), trastuzumab has little effect on ErbB2-ErbB3 ErbB2 heterodimerization with ErbB3
heterodimerization. and the pertuzumab binding site
A number of ErbB2 residues in and around the pertuzumab
binding site are homologous to EGFR residues necessary forSpecificity of pertuzumab for human ErbB2
Pertuzumab is specific for human ErbB2 and does not bind to homodimerization (Ogiso et al., 2002). To test the importance
of these residues in an ErbB2/ErbB3 heterodimer, alanine sub-rodent ErbB2 (neu) with detectable affinity (Fendly et al., 1990).
There are five residues in domain II which differ between human stitutions were made at ErbB2 residues Tyr 252, Phe 257, Glu
258, Phe 269, Leu 295, and His 296 corresponding respectivelyand rat ErbB2, and only two (Leu 295 and His 296) make signifi-
cant side chain contacts with the pertuzumab Fab (Figure 4B). to EGFR residues Tyr 246, Tyr 251, Gln 252, Phe 263, Ala 289,
and Asp 290; the ErbB2 double mutants Y252A/E258A, Y252A/Substitution of residues L295 and/or H296 in ErbB2 with neu
residues (L295P, H296N, or L295P/H296N) is sufficient to elimi- F263A, and L295A/H296A were also tested. Only the L295A/
H296A double mutant was able to impair HRG-dependent re-nate detectable binding to pertuzumab (Figure 3B). These sub-
stitutions also reduce the ability of pertuzumab to inhibit HRG- ceptor ErbB2-ErbB3 heterodimerization (Figure 4C), although
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smaller effects on heterodimerization could very well be below
the sensitivity limits of our assay. None of the other pertuzumab
contact single alanine mutations discussed above had any effect
on ErbB2 heterodimerization (Supplemental Figure S2).
Discussion
Pertuzumab binds at the ErbB2
heterodimerization interface
The central portions of domain II in ErbB2 and EGFR are highly
homologous and represent the majority of the dimerization inter-
face observed in EGFR (Garrett et al., 2002; Ogiso et al., 2002).
Since this region overlaps with the binding epitope of pertuzu-
mab (Figure 5A), an analysis of residues in this area should
shed light on both pertuzumab binding and ErbB2 dimerization.
Surface-exposed residues on pertuzumab and ErbB2 can be
part of one or both of two binding epitopes: a structural epitope,
defined by the contacts between the two molecules, and a
functional epitope, determined by previous mutagenesis of the
pertuzumab Fab (Vajdos et al., 2002) and our mutagenesis of
ErbB2. The overlap between these two epitopes (Figure 5) de-
fines the essential contacts between pertuzumab and ErbB2.
Pertuzumab’s light and heavy chains play different
roles in ErbB2 binding
The light chain of the pertuzumab Fab makes only a few contacts
with ErbB2, mostly via CDR L2, and none of the contact residues
affects ErbB2 binding when mutated (Vajdos et al., 2002). Con-
versely, light-chain residues which do affect binding when mu-
tated do so indirectly, since none of these residues contacts
ErbB2 (Figure 5B). The picture is quite different for the pertuzu-
mab heavy chain, where 24 residues contact ErbB2 directly;
seven of these affect binding by at least 75-fold when mutated Figure 5. The ErbB2 and pertuzumab binding epitopes
(Figure 5B). These essential residues form an extensive hydrogen
A: Overlap of dimerization and pertuzumab binding sites. ErbB2 is shown in
bond network with ErbB2, as discussed previously (Figure 2B), surface representation, colored as in Figure 1A. ErbB2 residues homologous
and occupy a compact patch on the surface of the pertuzumab to those EGFR residues which contact the dimerization hairpin are shown
in white (some atoms may be colored pink due to pertuzumab contact).Fab. Vajdos et al. (2002) observed a similar, if less compact, patch
Individual atoms in ErbB2 which directly contact pertuzumab atoms (3.2 A˚from their mutagenic analysis of the pertuzumab Fab alone.
distance) are shown in pink. ErbB2 residues mentioned in the text are la-
beled; those that inhibit pertuzumab binding when mutated to alanine are
Certain residues of ErbB2 are essential for pertuzumab boxed in red.
B: Overlap of the structural and functional ErbB2 binding regions. The molec-binding and heterodimerization
ular surface of the pertuzumab Fab is shown in an open book orientationOn the ErbB2 side of the interface, the S288A mutant is 6-fold
relative to A (i.e., the right side of B folds on top of the left side of A, so thatweaker in pertuzumab binding, probably due to the loss of the
pertuzumab residue 64 contacts the tip of the dimerization hairpin of ErbB2).
hydrogen bonds between Ser 288 of ErbB2 and Asp 31 of the Residues which do not contact ErbB2 are hatched. Residues which dis-
Fab. In contrast, Thr 290 also hydrogen bonds to Asp 31, yet played a75-fold loss in binding to ErbB2 when mutated to alanine (Vajdos
et al., 2002) are colored red; residues with a 10- to 75-fold loss in bindingthe T290A mutant has almost no detectable loss in pertuzumab
are colored yellow. The heavy black line separates the heavy chain (upperbinding. While our limited resolution prevents any detailed analy-
left) from the light chain (lower right) of the Fab.sis of hydrogen bonds, Ser 288 does make two hydrogen bonds
to pertuzumab, while Thr 290 only makes one, perhaps ex-
plaining the different effects of these mutations. The double
alanine substitutions V286A/H296A and L295A/H296A have the functionally relevant ErbB2-pertuzumab complex. To date,
dramatic effects on pertuzumab binding due to the loss of multi- mutations similar to the ones we have tested have not been
ple hydrophobic interactions with the Fab, as well as the hydro- reported in ErbB2 isolated from cancer patients.
gen bond to Tyr 99B. Additionally, pertuzumab will not bind to
rodent ErbB2 (Fendly et al., 1990), probably due to the substitu- Pertuzumab Fab sterically interferes
tion of a proline for Leu 295 and an asparagine for His 296. with ErbB2 heterodimerization
Indeed, the L295P/H296N double mutant of human ErbB2 is Our structure provides a clear explanation for the inhibition of
severely impaired in pertuzumab binding. The patch of pertuzu- ErbB2-mediated signaling by pertuzumab, and validates the
mab residues necessary for ErbB2 binding (Figure 5B) is mir- model of ErbB2 heterodimerization based on the structure of
rored by a cluster of ErbB2 residues important for pertuzumab the EGFR homodimer (Figures 6A–6H). The pertuzumab binding
epitope overlaps with a region which, by modeling and by ho-binding (Figure 5A), confirming that our structure has captured
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Figure 6. ErbB2 heterodimerization and pertuzu-
mab interference
Top-down (A, C, E, and G) and side (B, D, F,
and H) views of various states of the EGFR-ErbB2
heterodimerization process, modeled as de-
scribed in the Experimental Procedures. EGFR
and ErbB2 extracellular domains are shown in
surface representation, with EGFR and ErbB2 do-
mains I in green, II in blue, III in purple, and IV in
gray. EGFR is always on the left of the panel, and
ErbB2 on the right. EGF, when present, is shown
as an orange surface, while pertuzumab (G and
H) is shown as a pink surface. The lipid bilayer is
represented as tan spheres, with the modeled
transmembrane helices as black tubes. The di-
merization of the intracellular kinase domains of
EGFR (yellow surface) and ErbB2 (dark green sur-
face) is not meant to suggest the orientation of
the actual kinase dimer.
A and B: The closed (ligand-free) form of EGFR
is modeled near a molecule of ErbB2. In its unli-
ganded form, the extracellular domain of EGFR
(or ErbB3) is in a conformation which cannot di-
merize with another receptor (Cho and Leahy,
2002; Ferguson et al., 2003).
C and D: EGFR is now shown in its open, ligand-
bound state. Upon binding a ligand such as EGF,
EGFR rearranges into a conformation which ex-
poses the dimerization hairpin, shown protruding
from the center of domain II in light blue.
E and F: EGFR and ErbB2 are now hetero-
dimerized. The two receptors interact via each
one’s dimerization hairpin, the membrane-proxi-
mal portion of domain IV, and (at least in this
model) the transmembrane helices and intracel-
lular kinase domains. ErbB2 heterodimers with
EGFR, ErbB3, and ErbB4 are all expected to look
identical at this level of detail.
G and H: Pertuzumab has bound to ErbB2,
blocking heterodimerization by preventing the
EGFR dimerization hairpin from fitting in its binding
pocket on ErbB2.
mology with EGFR, is expected to be the binding site for the blocking the hairpin binding pocket is in fact sufficient to prevent
ErbB2 heterodimerization. Our structure shows that the pres-dimerization hairpin (Figures 5A and 6F); therefore, bound pertu-
zumab is modeled to sterically prevent the dimerization hairpin ence of the entire pertuzumab antibody is not needed to cause
this steric interference; the Fab fragment alone is sufficient, infrom reaching its binding pocket (Figures 6G–6H). The fact that
pertuzumab binding inhibits ErbB2 heterodimerization (Agus et agreement with our previous studies (Agus et al., 2002).
al., 2002) can now be interpreted in light of our structure as
experimental evidence supporting this dimerization model. Per- ErbB2 heterodimerization appears to be different
than EGFR homodimerizationtuzumab Fab bound to domain II would not sterically interfere
with other dimerization contacts, such as those in domain IV By binding to ErbB2 domain II, pertuzumab occludes a number
of residues which likely contact the other ErbB receptor in the(Figure 6F); if the dimerization hairpin could bend out of the
way, a receptor heterodimer could still potentially be formed. heterodimer (Figure 5A). We questioned which, if any, of these
residues was important for heterodimerization, and in particularThe conformation of this hairpin is nearly identical in all three
ErbB2 structures as well as the two EGFR homodimer structures whether mutations in this region have the same deleterious
effects in an ErbB2/ErbB3 heterodimer as they have been shown(Cho et al., 2003; Garrett et al., 2002, 2003; Ogiso et al., 2002),
suggesting that the hairpin is quite rigid and that sterically to have in an EGFR homodimer (Ogiso et al., 2002). In EGFR,
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residue 288 in ErbB2) in the modeled dimer partner, possibly
explaining the effects of the L295A/H296A mutation on hetero-
dimerization. The structure of this region is essentially the same
in Neu as in human ErbB2 (Cho et al., 2003), and Asn 296 in
Neu could make the same dimer interactions that His 296 does
in our model. An unresolved issue is that the single mutants,
L295A and H296A, show little or no effect on heterodimerization,
although we suspect that these mutants may have a small dele-
terious effect which is below the sensitivity limits of our hetero-
dimerization assay. Taken together, these structural and muta-
tional data suggest that the C-terminal portion of ErbB2 domain
II is involved in heterodimerization, and that some residues in
this region, in particular Leu 295 and His 296, are important for
heterodimerization as well as pertuzumab binding.
Interestingly, an ErbB2 homodimer cannot be modeled in
the same way as the ErbB2 heterodimer discussed above. The
last two disulfide-bonded modules of ErbB2 domain II would
Figure 7. Altered conformation of ErbB2 domain II be too close to the dimer interface, interpenetrating by more
The two copies of domain II (residues 188–313) from the EGFR dimer structure than 6 A˚ in the region of Ser 313 (Figure 7). At minimum, resolving
are shown as gray tubes. Domain II (residues 195–320) from ErbB2, superim-
this steric clash would require reorienting the two ErbB2 mole-posed on the central disulfide-bonded modules as described in the text, is
cules, possibly disrupting interactions involving the dimerizationshown as a blue tube. The last two disulfide-bonded modules from a copy
of ErbB2 superimposed on the other EGFR monomer are shown as a black hairpin or domain IV. This clash may combine with electrostatic
line to indicate the potential steric clash in this region. For clarity in this repulsion between ErbB2 monomers (Garrett et al., 2003) and
figure, the C backbone traces have been heavily smoothed. loss of interactions with the dimerization hairpin (Cho et al.,
2003) to explain why the extracellular domain of ErbB2 will not
homodimerize in solution (Ferguson et al., 2000); all of these
effects arise from the differences in domain II which give ErbB2residues Tyr 246 and Arg 285 interact across the dimer interface,
a unique role as a heterodimerization partner.as do Tyr 251 and Phe 263 (Garrett et al., 2002; Ogiso et al.,
In conclusion, our present study provides a satisfying struc-
2002). ErbB2 substitutes a leucine (Leu 291) for Arg 285 in
tural basis for pertuzumab’s effect as a heterodimerization inhib-
EGFR, breaking the first of these interactions. Therefore, the
itor. Bound pertuzumab occludes the pocket on ErbB2 that
ErbB2 mutations F257A and F269A, neither of which affects
would accept the dimerization hairpin of a heterodimer partner,
ErbB2/ErbB3 heterodimerization, are analogous to the EGFR preventing the association of the two receptors and subsequent
double mutants R285S/Y251A and R285S/F263A, which com- growth signaling. Pertuzumab therefore represents a novel class
pletely eliminate EGFR homodimerization (Ogiso et al., 2002). of targeted therapeutic agents, those that inhibit ErbB2’s func-
Other residues in this region of ErbB2 can also be mutated to tion as a coreceptor. The ErbB2-pertuzumab complex suggests
alanine with no effect on ErbB2/ErbB3 heterodimerization. Thus, that alternative antibodies, antibody fragments, or peptidomi-
our mutagenesis suggests that formation of ErbB2 heterodimers metics could also function as heterodimerization inhibitors. Re-
may be less dependent on correct contacts with the dimerization cently, pertuzumab has successfully completed phase I clinical
arm than formation of EGFR homodimers. testing. These studies suggest that the ErbB2 heterodimeriza-
tion inhibitor can be given safely to patients with advanced
Altered conformation of ErbB2 domain II suggests malignancies; in addition, pertuzumab produced an objective
a novel heterodimer contact response in some of these patients, all of whom had failed to
The conformation of ErbB2 is similar to that of activated, dimeric respond to one or more prior treatment programs. Ongoing
EGFR; however, small but significant differences in the shape phase II proof-of-concept studies will determine whether inhibi-
of domain II may explain the different dimerization properties tion of ErbB2 heterodimerization warrants further development
of these two receptors. Domain II of the ErbB receptors is rather in patients whose tumors lack ErbB2 gene amplification, but
like a spine, with rigid “vertebrae” (the disulfide-bonded mod- are instead driven by ligand-activated ErbB2.
ules) held in an overall conformation by domains I and III; these
Experimental proceduresdomains differ in orientation between EGFR and ErbB2 due to
the lack of an ErbB2 ligand (Figure 6D). As a result, the N-ter-
Cloning and expressionminal portion of ErbB2 domain II is farther from the modeled
Residues 1–624 of the extracellular domain of ErbB2 were stably expressed
dimer interface than in EGFR, while the C-terminal portion is and secreted in CHO cells as previously described (Hudziak and Ullrich,
closer (Figure 7). The last two disulfide-bonded modules of 1991). Conditioned media (100 liter), with an estimated ErbB2 concentration
EGFR domain II do not make significant dimer contacts in either 15 mg/L, was concentrated to 12 liter and frozen at 70 C for further
processing. Pertuzumab is built on the same antibody framework as trastu-EGFR homodimer structure, with C-C distances no less than
zumab (Carter et al., 1992). Selection and humanization of the pertuzumab10 A˚ (Garrett et al., 2002; Ogiso et al., 2002). In the modeled
antibody will be described elsewhere (C. Adams, D. Allison, J. Clark, B. Fan,ErbB2 heterodimer, this region is now in direct contact with the
T. Breece, C. Schmelzer, S. Brignoli, K. Totpal, G. Phillips, L. Presta, and
other receptor, with a C-C distance as low as 4.5 A˚. His M.X.S., unpublished data). The heavy and light chains of the pertuzumab
296 is in this region, and has been placed relatively close to a Fab fragment were coexpressed into the periplasm of the 33B6 strain of E.
coli under the control of an alkaline phosphatase promoter, using an expres-conserved aspartate (residue 279 in EGFR, ErbB3, and ErbB4;
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sion system originally developed for an anti-LFA-1 Fab (Werther et al., 1996). is quite poor (C rmsd 6 A˚). Superposition by domain lowers the C
Cells (1900 g) were harvested from a 10 liter fermentation and frozen at70 rmsd to 2–3 A˚ depending on the domain, but raises the question of which
C in 200 g batches. superposition to use for the modeling. Since nearly all of the dimerization
contacts in EGFR lie in domain II, this is the logical choice for superposition
Protein purification when making a heterodimer model. Further analysis (see Discussion and
ErbB2 extracellular domain (ECD) was purified by immunoaffinity and gel Figure 7) shows that only residues 232–292 of ErbB2 (EGFR residues 226–
filtration chromatography. A trastuzumab affinity column was prepared by 286) should be included in the superposition. These residues superimpose
coupling 400 mg trastuzumab (intact MAb; Genentech, Inc.) to 40 g CNBr- well, with a C rmsd of 1.3 A˚ (excluding only two residues at the tip of the
activated sepharose (Pharmacia); the resulting 100 ml column has the capac- dimerization hairpin). Domain IV of EGFR is disordered or not present in the
ity to bind at least 200 mg of ErbB2 ECD. Concentrated ErbB2 ECD from dimeric EGFR structures (Garrett et al., 2002; Ogiso et al., 2002), but can
conditioned CHO cell medium was applied to the trastuzumab column, be plausibly inferred by superposition of domains III and IV from the closed
eluted with 10 mM HCl, and immediately neutralized with 1 M Tris (pH 8.0). form of EGFR (Ferguson et al., 2003) onto domain III of the dimeric form.
Fractions containing ErbB2 ECD were concentrated and passed over a This superposition places the C termini of the modeled extracellular domains
Superdex-200 column (Pharmacia) to separate monomeric protein from di- of EGFR and ErbB2 in close proximity, allowing the modeled transmembrane
sulfide-linked aggregates. The purified protein was stored at 4C in PBS 	 helices to associate. Transmembrane helices and linker peptides were cre-
0.02% sodium azide. ated de novo, and two copies of the kinase domain of EGFR (Stamos et al.,
Pertuzumab Fab was also purified by affinity and gel filtration chroma- 2002) were placed next to each other in an arbitrary orientation, not one of
tography. Briefly, the Fab was released from E. coli cells using osmotic
the previously proposed ErbB kinase dimer models (Groenen et al., 1997;
shock by resuspending frozen cells in 0.1 M acetic acid (pH 3), 25 mM
Murali et al., 1996).
EDTA, 1 mM PMSF. Impurities were removed from the shockate by batch
While there is no structure of ErbB3 in its ligand-bound, active form,
binding to DEAE-sepharose (Pharmacia) at 0.5 ml resin per gram of cells. The
the inactive forms of EGFR and ErbB3 show a remarkable similarity to one
processed shockate was then passed over a protein G-sepharose column
another, with C rmsds for domains I, III, and IV of 0.9–1.2 A˚ (and 1.9 A˚ for(Pharmacia) to trap the Fab, and the column was then washed with 10 mM
domain II). To a first approximation, therefore, an EGFR/ErbB2 heterodimerMES (pH 5.5), 10 mM EDTA. Bound Fab was subsequently eluted with 0.1
model will be identical to an ErbB3/ErbB2 heterodimer model, with theM acetic acid, and the eluate was neutralized with 1 M Tris (pH 8.0). The
caveat that the heterodimerized conformation of ErbB3 (or EGFR) may notpooled Fab-containing fractions were further purified by Superdex-200 gel
be the same as that of homodimeric EGFR.filtration. Purified pertuzumab Fab, like purified ErbB2 ECD, is very stable
in PBS 	 0.02% sodium azide. Early crystallization trials used protein pro-
ErbB2 mutagenesis and COS-7 transfectionsduced by a different method (Vajdos et al., 2002); however, the crystals
All wild-type and ErbB2 mutant constructs used in this study were epitope-were identical to those described here.
tagged at the N terminus with the herpes simplex virus signal sequence of
gD replacing the endogenous ErbB2 signal sequence (Schaefer et al., 1999).ErbB2-pertuzumab complex preparation and crystallization
Mutations were introduced into a 1.5 Kb EcoR1-XhoI restriction fragmentErbB2 (10.5 mg at 3.5 mg/ml) and pertuzumab Fab (10.1 mg at 1.3 mg/ml)
of ErbB2 in pBSKS- (Stratagene) using the Quick-change method followingwere mixed (a 33% molar excess of pertuzumab) and allowed to incubate
manufacturer’s recommendations (Stratagene). Mutants were then sub-overnight at 4C. The complex was then separated from excess pertuzumab
cloned into the EcoRI-XhoI site of full-length gDErbB2 in a pRK5 mammalianFab by running over a Superdex-200 column in PBS. The purified complex
was concentrated to 10 mg/ml and stored for crystallization in 25 mM Tris expression vector. All mutations were confirmed by automated DNA se-
(pH 8.0), 150 mM NaCl, 0.1 mM EDTA. quencing. COS-7 cells (1 
 106 cells/10 cm dish) were transfected with 1 g
The purified ErbB2-pertuzumab complex was mixed 1:1 with well solu- of pRK5.gDErbB2 wild-type or pRK5.gDErbB2 mutant DNA with or without
tion (22% PEG 3350, 100 mM ammonium formate) and equilibrated by 10 g of pRK7.ErbB3 DNA as described using LipofectAMINE according to
hanging- or sitting-drop vapor diffusion against the well solution. The pH of the manufacturer’s recommendations (Invitrogen). Twenty-four hours post-
this mother liquor is not well defined, since there is no buffering capacity at transfection, cells were serum starved overnight in 0.1% fetal bovine serum/
neutral pH except for the residual Tris from the protein storage solution; DMEM at 37C prior to treatment.
however, the pH of 100 mM ammonium formate is 6.5. Tetragonal bipyra-
mids appear in a few days and grow to 100–200 micron size in a week. Pertuzumab binding assays
Crystals were removed from their mother liquor and cryostablized in 100 The relative affinity of pertuzumab Fab for ErbB2 or ErbB2 mutants was
mM ammonium formate, 25% PEG 3350, 20% ethylene glycol, then frozen measured by ELISA. COS-7 cells were transfected with 10g of pRK5.gDErbB2
in liquid nitrogen. or pRK5.gDErbB2 mutant plasmids. After 24 hr, cells were lysed in 1 ml of
lysis buffer (1% Triton X-100, 1% CHAPS, 25 mM Tris [pH 8.0], 150 mM
Data collection and structure determination NaCl, 0.5 mM PMSF, 10 U/ml aprotinin, and 10 g/ml leupeptin). Lysates
Data for the ErbB2-pertuzumab complex were collected at Beamline 5.0.1
were normalized to 1 ng/ml gDErbB2 protein using the purified soluble
of the Advanced Light Source (Berkeley). Highly redundant data were col-
extracellular domain of ErbB2 as a standard (Vajdos et al., 2002) as quantified
lected to help counteract the generally weak diffraction. Data statistics are
by an ORIGEN assay using 2 g/ml biotinylated anti-gD antibody 5B6 for
shown in Table 1. A molecular replacement solution for the ErbB2 portion
capture and 0.5 g/ml ori-tagged trastuzumab for detection via an Origenof the complex was obtained using AMoRe (Navaza, 1994), with the structure
analyzer following manufacturer’s instructions (IGEN).of rat ErbB2 (Cho et al., 2003) as a search model. Once both ErbB2 molecules
Nunc maxisorp plates (Nunc) were coated with 5 g/ml anti-gD tagin the asymmetric unit were found, further molecular replacement using the
capture antibody (3C8) in PBS overnight at 4C, and blocked for two hoursvariable domain of the pertuzumab Fab (Vajdos et al., 2002) identified the
with 5% bovine serum albumin (Sigma) in PBS. Normalized lysates werelocation of the two pertuzumab molecules. Initial rigid-body refinement of
added to coated ELISA plates and allowed to bind for 2 hr at 4C. Platesthe various domains of the complex was performed using CNX (Accelrys,
were rinsed with PBS/0.1% Tween 20, and serial dilutions of purified pertuzu-Inc.) without enforcing the noncrystallographic symmetry. Subsequent posi-
mab Fab were added to the plates in PBS and allowed to bind for 2 hr. Platestional and restrained individual atomic B factor refinement was performed
were rinsed with PBS/0.1% Tween 20, and an anti-human Fab-specific HRPusing CNX and Refmac5 (Murshudov et al., 1997), with fairly tight NCS
conjugated antibody (Biosource) was added at 1/5000 dilution in PBS/1%restraints to prevent overrefinement. Model statistics are in Table 1.
BSA/0.1% Tween for 1 hr. Plates were rinsed 6
 with PBS/0.1% Tween,
and bound gDErbB2 was detected using TMB as a substrate (Sigma) andModeling of an ErbB2 heterodimer
measured at 490 nm using a plate reader. The EC50 for each mutant wasModeling of an ErbB2-containing heterodimer used the EGFR homodimer
calculated from the binding curves using a 4 parameter fit function, andstructure (Ogiso et al., 2002) as a starting point, with ErbB2 superimposed
relative affinities were estimated by dividing the EC50 of each mutant by theonto one of the two EGFR molecules. Because of the altered global confor-
mation of ErbB2 versus EGFR, a global superposition of the two molecules EC50 of wild-type gDErbB2.
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D.J., Lemmon, M.A., Sliwkowski, M.X., Ward, C.W., and Yokoyama, S.Coimmunoprecipitation assays
(2003). An open-and-shut case? Recent insights into the activation of EGF/Activation of ErbB2 was evaluated by heterodimerization with ErbB3 upon
ErbB receptors. Mol. Cell 12, 541–552.heregulin (HRG) stimulation in a coimmunoprecipitation assay (Agus et al.,
2002). Prior to stimulation, the medium was changed to fresh DMEM with Carter, P., Presta, L., Gorman, C.M., Ridgway, J.B., Henner, D., Wong,
or without 100 nM pertuzumab or trastuzumab for 1 hr prior to stimulation W.L., Rowland, A.M., Kotts, C., Carver, M.E., and Shepard, H.M. (1992).
as indicated. COS-7 cells were stimulated for 10 min at room temperature Humanization of an anti-p185HER2 antibody for human cancer therapy.
with 2 nM of recombinant heregulin (HRG1177–244), in binding buffer (RPMI Proc. Natl. Acad. Sci. USA 89, 4285–4289.
medium, 0.02% BSA, 10 mM Hepes [pH 7.2]) or binding buffer alone as
Carter, P., Fendly, B.M., Lewis, G.D., and Sliwkowski, M.X. (2000). Develop-described. Transfected cells were lysed in 1 ml RPMI lysis buffer (1% v/v
ment of Herceptin. Breast Disease 11, 103–111.Triton X-100, 1% w/v CHAPS, 10 mM HEPES (pH 7.2), in RPMI medium
containing 0.2 mM PMSF, 10 g/ml leupeptin, 10 U/ml aprotinin, and 1 mM Cho, H.S., and Leahy, D.J. (2002). Structure of the extracellular region of
Na3VO4). Heterodimers were immunoprecipitated from 500 l of lysate using HER3 reveals an interdomain tether. Science 297, 1330–1333.
rabbit polyclonal anti-ErbB3 antibody (Santa Cruz) covalently coupled to
Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney,agarose (Pierce ultralink) at 4C for 2 hr. Complexes were washed twice in
D.W., Jr., and Leahy, D.J. (2003). Structure of the extracellular region oflysis buffer and resuspended in SDS sample buffer and boiled. Samples
HER2 alone and in complex with the Herceptin Fab. Nature 421, 756–760.
were separated on a 4%–12% polyacrylamide gel (Novex) and electroblotted
onto nitrocellulose membranes. Blots were blocked in 5% BSA/TBST and Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000). Inhibitory
Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med.probed with either phosphospecific anti-ErbB2 antibody (Neomarkers), or
6, 443–446.an anti-gD epitope monoclonal antibody (5B6) to detect gDErbB2 followed
by a peroxidase-conjugated anti-mouse secondary antibody (Amersham).
Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehren-
To verify and normalize for expression of transfected constructs between bacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., and Slamon,
experimental conditions, 50 g of cell lysate was checked by Western blot- D.J. (1999). Multinational study of the efficacy and safety of humanized
ting with anti-gD antibody (5B6) or anti-ErbB3 (Ab7, Neomarkers) antibody. anti-HER2 monoclonal antibody in women who have HER2-overexpressing
Anti-mouse HRP-conjugated secondary antibody was used for visualization metastatic breast cancer that has progressed after chemotherapy for meta-
by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech). static disease. J. Clin. Oncol. 17, 2639–2648.
Eigenbrot, C., Randal, M., Presta, L., Carter, P., and Kossiakoff, A.A. (1993).Phosphorylation assays
X-ray structures of the antigen-binding domains from three variants of hu-Pertuzumab inhibition of HRG-dependent activation of gDErbB2 or gDErbB2
manized anti-p185HER2 antibody 4D5 and comparison with molecular mod-mutants was detected by a tyrosine phosphorylation assay as previously
eling. J. Mol. Biol. 229, 969–995.described (Schaefer et al., 1999).
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